KPIs & Operating Metrics(New)
Breakdown Of AssetsCost Of Product SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitOpex As A % Of Total Revenue %OPEX SegregationProperty And EquipmentRevenue By Category Contract Revenue From CollaborationsRevenue By Category Contract Revenue From Collaborations AnnualRevenue By Collaborative Partners AnnualRevenue By Major CustomersRevenue By Major Customers %Revenue By Major Customers AnnualRevenue By Major Customers Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Bottles ShippedTotal Bottles Shipped Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Rigel Pharmaceuticals (RIGL) Gross Profit (2016 - 2025)

Rigel Pharmaceuticals has reported Gross Profit over the past 8 years, most recently at $63.8 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 23.24% year-over-year to $63.8 million; the TTM value through Dec 2025 reached $274.7 million, up 70.99%, while the annual FY2025 figure was $274.7 million, 70.99% up from the prior year.
  • Gross Profit for Q4 2025 was $63.8 million at Rigel Pharmaceuticals, down from $64.7 million in the prior quarter.
  • Over five years, Gross Profit peaked at $97.2 million in Q2 2025 and troughed at $16.6 million in Q1 2022.
  • A 5-year average of $40.6 million and a median of $30.4 million in 2022 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: tumbled 79.41% in 2022 and later skyrocketed 185.54% in 2025.
  • Year by year, Gross Profit stood at $19.9 million in 2021, then soared by 155.68% to $50.9 million in 2022, then crashed by 37.17% to $32.0 million in 2023, then surged by 61.89% to $51.8 million in 2024, then grew by 23.24% to $63.8 million in 2025.
  • Business Quant data shows Gross Profit for RIGL at $63.8 million in Q4 2025, $64.7 million in Q3 2025, and $97.2 million in Q2 2025.